<DOC>
	<DOC>NCT01908465</DOC>
	<brief_summary>Purpose: To evaluate the efficiency of Irritable Bowel Syndrome (IBS) patients treatment with the H1-receptor antagonist ebastine. Design: Double blind randomized placebo controlled trial. IBS patients receive a 12-weeks treatment with ebastine 20mg once daily or placebo (1:1 randomization).</brief_summary>
	<brief_title>Peripheral Histamine 1 Receptor Blockade in IBS: Multicenter Trial</brief_title>
	<detailed_description />
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Histamine</mesh_term>
	<mesh_term>Histamine phosphate</mesh_term>
	<mesh_term>Ebastine</mesh_term>
	<criteria>Irritable Bowel Syndrome (IBS) (ROME III criteria): subtype with diarrhea or mixed form age 1865 years IBS subtype with constipation medication: antidepressants or H1receptor antagonists pregnancy, breast feeding comorbidity: severe kidney and/or liver disease or other gastrointestinal diseases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>